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The PROLONG study showed that patients with venous thromboembolism who had qualitative-
ly abnormal results in a D-dimer assay (Clearview Simplify D-dimer) after discontinuation of
vitamin K antagonism benefit from resumption of treatment with vitamin K antagonism. The
objective of this study was to evaluate the possible advantage of using quantitative D-dimer
assays.
Design and Methods
VIDAS D-dimer Exclusion (bioMerieux), Innovance D-DIMER (Dade Behring), HemosIL D-dimer
HS (Instrumentation Laboratory) and STA Liatest D-dimer (Diagnostica Stago) assays were per-
formed in plasma aliquots sampled 30±10 days after cessation of vitamin K antagonism in
321 patients enrolled in the PROLONG study.
Results
During the follow-up without vitamin K antagonism, 25 patients had recurrent venous throm-
boembolism. The cut-off levels of the quantitative assays giving results most comparable with
those of the qualitative test were: VIDAS = 800 ng/mL; Innovance = 800 ng/mL; HemosIL HS
= 300 ng/mL; STA Liatest = 700 ng/mL. When the effect of the patients’ age (≤70 vs. >70
years) was analyzed, it was found that only in younger patients was the rate of recurrence of
venous thromboembolism significantly higher in patients with abnormal D-dimer levels.
However, using the quantitative assays and age-specific cut-off levels it was possible to deter-
mine statistically significant hazard ratios also in elderly patients (VIDAS = 600 and 1200
ng/mL, Innovance = 500 and 900 ng/mL, HemosIL HS = 250 and 450 ng/mL, STA Liatest =
700 and 1000 ng/mL, in patients aged ≤70 and >70 years, respectively).
Conclusions
Quantitative D-dimer assays may provide information useful for evaluating the individual risk of
recurrent venous thromboembolism. They seem particularly advantageous since they allow the
selection of different cut-off levels according to the age or other characteristics of the patients.
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Introduction
Unprovoked venous thromboembolism (VTE) recurs
frequently after discontinuation of treatment with vita-
min K antagonists with about 50% of patients suffering
from recurrence within 10 years of the incident event.
The incidence of VTE recurrence does, however, vary
with time and is highest (about 10-15%) over the 6-12
month period after the incident event.1 Treatment with
vitamin K antagonists is effective in preventing recur-
rent VTE,2-4 but the duration of anticoagulation does
not seem to affect the risk of recurrence once primary
therapy for the incident event is stopped.5-7 Since the
risk of vitamin K antagonist-related bleeding does not
decrease with time 3 months after the start of therapy8
(but indeed increases with age), the benefit of pro-
longed vitamin K antagonism diminishes over time.
Indefinite secondary prophylaxis with vitamin K antag-
onists in all patients with previous unprovoked VTE
should, therefore, be carefully assessed and should be
limited to those patients with the highest risk of recur-
rence. 
Earlier prospective studies in patients with VTE9-12
demonstrated that D-dimer levels have a strong predic-
tive value for the occurrence of subsequent episodes.
These studies suggested that D-dimer measurement
may have a role in gauging the duration of anticoagula-
tion in patients with VTE. The recently published PRO-
LONG study,13 a prospective, randomized, multicenter
study investigating patients after a first episode of
symptomatic unprovoked VTE, showed that patients
with abnormal D-dimer levels after withdrawal of anti-
coagulation had a higher rate of VTE recurrence than
those with normal D-dimer levels and benefited from
resumption of anticoagulation. 
Since PROLONG was a multicenter study and D-
dimer measurements needed to be performed with the
same test in all participant centers, a qualitative D-
dimer assay was chosen (Clearview Simplify D-dimer
by Inverness Medical Professional Diagnostics). This
test can be performed on citrated whole blood and the
result (negative or positive) evaluated visually. In prin-
ciple, however, the accuracy of D-dimer assays may be
enhanced by using quantitative tests with appropriate
cut-off values. 
The present study retrospectively analyzed a sub-
group of patients enrolled in the PROLONG study. Its
main aims were to assess the performance of four
quantitative D-dimer methods to predict the risk of
VTE recurrence and to verify whether the adoption of
different cut-off values may help to distinguish better
between subjects with higher or lower risk of recur-
rence. 
Design and Methods
Patients and study design
As described in detail elsewhere,13 the PROLONG
study was a multicenter prospective study performed
in 30 centers belonging to the Italian Federation of
Thrombosis Centers (FCSA). In brief, between
September 2002 and January 2005, consecutive patients
referred for a first episode of symptomatic unprovoked
VTE, including proximal deep vein thrombosis (DVT)
of the legs and/or pulmonary embolism (PE), and who
were treated with a vitamin K antagonist for a mini-
mum of 3 months were eligible. Unprovoked VTE was
defined as episodes not associated with pregnancy or
puerperium, recent (i.e. within 3 months) fracture or
plaster casting of a leg, immobilization with confine-
ment to bed for 3 or more consecutive days, surgery
with general anesthesia lasting 30 or more minutes,
active cancer, antiphospholipid antibody syndrome, or
antithrombin deficiency. At the end of the vitamin K
antagonist treatment, candidate subjects had a medical
examination to assess their baseline clinical condition.
Patients were instructed to stop oral anticoagulation
immediately and refrain from taking any other
antithrombotic drugs until the next visit, scheduled
after 30±10 days. At that visit, D-dimer levels were
assessed using the qualitative Clearview Simplify D-
dimer assay. Patients with normal Clearview Simplify
D-dimer results (n=385) did not resume anticoagula-
tion, whereas those with abnormal results were ran-
domized to either resume (n=103) or not (n=120) anti-
coagulation with a vitamin K antagonist, with the aim
of maintaining the International Normalized Ratio
(INR) between 2.0 and 3.0, during the entire follow-up
period of 18 months. From the assignment visit, all
patients were followed up for a maximum duration of
18 months and were seen at the clinical center at 3- to
6-month intervals. The results were analyzed according
to the intention-to-treat principle. The Ethics
Committee of all participating clinical centers approved
the study. All enrolled patients provided written
informed consent. 
At the visit scheduled 30±10 days after interruption
of vitamin K antagonist treatment, besides performing
the Clearview Simplify D-dimer assay, the participat-
ing centers were also asked to collect plasma aliquots
for further centralized analyses; a total of 386 plasma
aliquots were collected and stored in 14 participating
centers. The present analysis was centrally performed
using plasma samples from 321 patients, 240 with nor-
mal Clearview Simplify D-dimer results and 81 with
abnormal results; the 65 samples collected from sub-
jects with abnormal Clearview Simplify D-dimer
results who had been randomized to resume treatment
with vitamin K antagonist were excluded. 
This analysis considered the same outcome as in the
PROLONG study: objectively documented recurrence
of DVT and/or PE.13
Blood sampling and D-dimer tests
Blood was collected from the antecubital vein into
0.129 mmol/L trisodium citrate; plasma was prepared
by centrifugation for 20 min at 2000 g at room temper-
ature. Platelet-poor plasma was distributed into coded
plastic tubes, snap-frozen and stored locally at -70°C.
Frozen aliquots were then sent by courier to the coor-
dinating center in dry ice and stored at -70°C. The
Clearview Simplify D-dimer assay (Inverness Medical
Professional Diagnostics, Bedford, UK and Luisville,
Colorado, USA; kindly provided by Instrumentation
Laboratory, Milan, Italy) was performed locally in each
center on fresh citrated whole blood.
In the present study, we report the results obtained
with four quantitative D-dimer assays which were per-
formed centrally in the laboratory of the co-ordinating
center at the end of the follow-up of the PROLONG
study. These D-dimer tests were performed (after
thawing the frozen aliquots for 5 minutes in a water-
bath at 37°C) by technicians unaware of the clinical
characteristics of the patients. The following assays
were performed: (i) VIDAS D-dimer Exclusion
(bioMerieux, Lyon, France; kindly provided by the
manufacturer) on a VIDAS apparatus (bioMerieux); the
calibration curve stored in the memory for each lot was
reset every 14 days using a provided calibrator; (ii)
Innovance D-DIMER (Dade Behring, Marburg,
Germany; kindly provided by the manufacturer) on a
BCS instrument (Dade Behring); calibration was per-
formed using the calibrator included in the kit and was
carried out monthly or when a new lot was used; (iii)
HemosIL D-dimer HS (Instrumentation Laboratory;
kindly provided by the manufacturer) on an ACL TOP
instrument (Instrumentation Laboratory); calibration
was performed using the D-dimer calibrator included
in the kit and was carried out monthly or when a new
lot was used; and (iv) STA Liatest D-dimer (Diagnostica
Stago, Asnieres-sur-Seine, France; kindly provided by
Roche Diagnostics, Monza, Italy) on a STA Compact
instrument (Diagnostica Stago); a calibration curve
stored in the memory for each lot was used. 
The results of VIDAS D-dimer Exclusion, Innovance
D-DIMER and STA Liatest D-dimer are expressed in
ng/mL of fibrinogen equivalent units, since these assays
use crude plasmin digested lysates of cross-linked fibrin
clots as calibrators. The calibrator used in the HemosIL
D-dimer HS assay, however, consists of purified D-
dimer fragments obtained from a plasmin-digested clot
and so the results of this assay are expressed in ng/mL
of D-dimer units. Since one D-dimer unit corresponds
roughly to two fibrinogen equivalent units, the values
obtained with the HemosIL D-dimer HS are expected
to be about half those of the other assays.
Statistical analysis
Continuous variables are presented as median
(range). Hazard ratios (HR) and 95% confidence inter-
vals (CI) were calculated using a Cox proportional-haz-
ard model. The SPSS statistical software package
(Version 11.0, Chicago, Ill, USA) was used for data pro-
cessing.
Results
The demographic and clinical characteristics of the
321 patients whose plasma samples were analyzed in
the present study are presented in Table 1. As shown in
the table, no differences were found in the characteris-
tics between these patients and those included in the
original PROLONG study who did not resume treat-
ment with a vitamin K antagonist (n=505).
The Clearview Simplify D-dimer test gave normal
result for 240 (74.8%) patients and abnormal results for
81 (25.2%) patients who were randomized not to
resume vitamin K antagonist treatment. During follow-
up, 25 patients had recurrent VTE (7.8%; 95%CI: 5.9-
11.3) [DVT in 21 (14 contralateral, 2 with PE) and iso-
lated PE in 4 cases; 16 males]. The incidence rate was
5.5 per 100 person-years. There was no significant dif-
ference in duration of vitamin K antagonist treatment
between patients with [8.0 months (range: 3.0-33.0)] or
without [8.5 months (range: 4.9-105)] recurrence. VTE
recurrence occurred in 13 (5.4%) of the 240 patients
with normal Clearview Simplify D-dimer test results
and in 12 (14.8%) of the 81 with abnormal results
(HR=2.94; 95%CI: 1.34-6.45). The incidence rate of
VTE recurrence was 11.0 and 3.7 per 100 person-years
in patients with abnormal and normal Clearview
Simplify D-dimer results, respectively.
Table 2 shows the results calculated for each quanti-
tative D-dimer assay using the cut-off value indicated
by the manufacturers for diagnostic strategies regarding
exclusion of VTE in symptomatic patients. The results,
also calculated at different cut-off levels (see Figure 1),
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Table 1. Baseline characteristics of the 321 enrolled patients. 
Present Original 
study PROLONG study
Sex [male/female] 173/148 262/243
Age, years [median (range)]
> 70 years, n. (%) 67 (20-84) 65 (19-84)
125 (38.9) 198 (39.2)
Site of the first VTE
Proximal DVT, n, (%) 194 (60.5) 314 (62.2)
Proximal DVT + PE, n, (%) 64 (19.9) 93 (18.4)
Isolated PE, n, (%) 63 (19.6) 98 (19.4)
Congenital thrombophilic alterations
Factor V Leiden mutation, n, (%) 30 (9.3) 45 (8.9)
G20210A prothrombin mutation, n, (%) 20 (6.2) 33 (6.5)
Combined alterations or homozygous mut., 8 (2.5) 9 (1.8)
n. (%)
Duration of previous VKA treatment
≤ 6 months, n. (%) 62 (19.3) 81 (16.0)
> 6 months, n. (%) 259 (80.7) 424 (84.0)
Clearview Simplify D-dimer results
Normal, n. (%) 240 (74.8) 385 (76.2)
Abnormal, n. (%) 81 (25.2) 120 (23.8)
Total duration of follow-up, years 458.9 692.0
Follow-up, days [median (range)] 600 (3-600) 600 (3-600)
VTE recurrences
n (%) 25 (7.8) 42 (8.3)
% patients/years 5.5 6.1
No differences were found between the characteristics of the patients considered in
the present study and those patients (n=505) included in the original PROLONG
study who did not resume VKA treatment.
VKA: vitamin K antagonists; VTE: venous thromboembolism; DVT: deep vein
thrombosis; PE: pulmonary embolism. 
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were similar for all the evaluated tests. By increasing
the cut-off level fewer patients had abnormal D-dimer
results and the percentage of VTE recurrences in these
patients increased; however, the absolute number of
VTE recurrences in this kind of patient decreased. In
patients with normal D-dimer levels the absolute num-
ber of VTE recurrences raised in step with increasing
cut-off values; however, the percentage of VTE recur-
rences did not change significantly. Indeed, the nega-
tive predictive values at the lowest and highest cut-off
levels were, respectively: VIDAS D-dimer Exclusion =
97.4% and 95.1%; Innovance D-DIMER = 95.7% and
93.8%; HemosIL D-dimer HS = 95.8% and 94.4%; and
STA Liatest D-dimer = 95.9% and 94.4%. Table 2 also
reports the results obtained using as the cut-off level
the one giving results most comparable to those
obtained with the Clearview Simplify D-dimer assay:
VIDAS D-dimer Exclusion = 800 ng/mL; Innovance D-
DIMER = 800 ng/mL; HemosIL D-dimer HS = 300
ng/mL; and STA Liatest D-dimer = 700 ng/mL. We also
calculated the incidence rate of VTE recurrence per 100
person-years in patients with abnormal and normal D-
dimers results using different cut-off levels for each
quantitative D-dimer assay (Figure 2). At the cut-off
levels providing the results most comparable to those
obtained with the Clearview Simplify D-dimer assay,
Figure 1. Results of quantitative D-dimer
assays calculated using different cut-off
levels. The solid lines represent the per-
centage of patients with D-dimer above
the corresponding cut-off level (abnormal
D-dimer); the dashed and dotted lines
represent the percentages of recurrent
venous thromboembolism in patients
with abnormal or normal D-dimer levels,
respectively.
Figure 2. Incidence rate of venous throm-
boembolism recurrence per 100 person-
years calculated using different cut-off
levels for quantitative D-dimer assays.
The solid lines represent the incidence
rates in patients with D-dimer above the
corresponding cut-off level (abnormal D-
dimer); the dotted lines represent the
incidence rates in patients with D-dimer
below the corresponding cut-off level
(normal D-dimer). The solid and dotted
horizontal lines indicate the incidence
rates of recurrent venous thromboem-
bolism in patients with, respectively,
abnormal or normal results in the
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the incidence rates in patients with abnormal/normal
D-dimer levels were: VIDAS D-dimer Exclusion =
11.6/3.5 per 100 person-years; Innovance D-DIMER =
12.2/2.9 per 100 person-years; HemosIL D-dimer HS =
11.4/3.9 per 100 person-years; and STA Liatest D-dimer
= 13.2/4.8 per 100 person-years.
Hazard ratios were also calculated according to the
patients’ age (≤70 vs. >70 years). For quantitative D-
dimer assays, results were calculated using a unique
cut-off level (that giving results most comparable to
those obtained with the Clearview Simplify D-dimer
assay, mentioned above and presented in Table 2). As
shown in Table 3, the risk of VTE recurrence was sig-
nificantly higher in patients with abnormal vs. normal
D-dimer levels according to both the qualitative and all
the quantitative D-dimer assays only among the
patients ≤70 years old. Furthermore, the percentage of
patients with abnormal D-dimer levels in both qualita-
tive and quantitative D-dimer assays was significantly
higher (2- to 3-fold) in patients aged over 70 than in
those ≤70 years old.
Results were also calculated for the quantitative D-
dimer assays using different cut-off levels according to
the patients’ age (data not shown). Table 4 reports the
results obtained in patients aged ≤70 and > 70 years.
For each assay the results calculated using the lowest
cut-off level giving a statistically significant hazard
ratio are reported (patients aged ≤70 years: VIDAS D-
dimer Exclusion = 600 ng/mL, Innovance D-DIMER =
500 ng/mL, HemosIL D-dimer HS = 250 ng/mL, and
STA Liatest D-dimer=700 ng/mL; patients aged >70
years: VIDAS D-dimer Exclusion=1200 ng/mL; Inno-
vance D-DIMER=900 ng/mL; HemosIL D-dimer HS =
450 ng/mL; STA Liatest D-dimer = 1000 ng/mL). As
shown in Table 4, to obtain statistically significant haz-
ard ratios higher cut-off levels should be used for elder-
ly patients.
Discussion
D-dimer levels are currently the most widely used
laboratory marker for in vivo clotting activation, mainly
due to their important role in excluding VTE in symp-
tomatic patients.14-17 Despite the widespread use of D-
dimer measurement, clinicians are puzzled by the high
variability in numerical results produced by the differ-
ent methods now available. Indeed, one of the main
problems of D-dimer assays is that it is not currently
possible to standardize results from different assays,18-23
making it difficult to extrapolate results from one set-
ting to another. Each assay should, therefore, be vali-
dated separately by rigorous clinical and management
studies.
Recently, the PROLONG study13 evaluated the role of
D-dimer levels in tailoring the duration of treatment
with a vitamin K antagonist in patients with a previous
unprovoked VTE episode. The results of that study
indicate that patients with altered D-dimer levels,
assessed 1 month after withdrawal of vitamin K antag-
onism, have a significantly higher risk of VTE recur-
rence and benefit from prolonged treatment with a
vitamin K antagonist. As PROLONG was a multicenter
study, the same D-dimer test needed to be used in all
participating centers. The qualitative Clearview
Simplify D-dimer assay was chosen for this purpose;
this assay can be performed on citrated whole blood
and does not require any instrumentation. The use of
qualitative D-dimer tests is not generally recommend-
ed; observer-independent tests should be preferred in
daily clinical practice in which operating conditions are
less stringent than those in clinical studies. On the
other hand, the choice of any other quantitative test
would not have solved the question of between-assay
comparability due to poor standardization of D-dimer
methods. Given the poor standardization, if a D-dimer
C. Legnani et al. 
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Table 2. Results obtained with the different D-dimer assays in all patients. The table reports the results calculated using the cut-off levels
indicated by the manufacturers to be used in diagnostic strategies for the exclusion of venous thromboembolism in symptomatic patients
and the cut-off levels giving the results most comparable to those obtained with the qualitative Clearview Simplify D-dimer assay.
D-dimer assay Cut-off N. (%) of patients N. (%) of VTE N. (%) of VTE HR 
(n. of tested patients) with abnormal recurrences in patients recurrences in patients (95%CI) 
D-dimer with abnormal with normal 
D-dimer D-dimer
Clearview Simplify D-dimer ------ 81 (25.2) 12 (14.8) 13 (5.4) 2.94 (1.34-6.45)
(n=321)
VIDAS D-dimer Exclusion 500 ng/mLa 160 (50.5) 17 (10.6) 8 (5.1) 2.08 (0.93-4.69)
(n=317) 800 ng/mLb 86 (27.1) 13 (15.1) 12 (5.2) 3.23 (1.47-7.08)
Innovance D-DIMER 500 ng/mLa 109 (43.2) 14 (12.8) 7 (4.9) 2.62 (1.10-6.28)
(n=252) 800 ng/mLb 57 (22.6) 10 (17.5) 11 (5.6) 3.41 (1.45-8.03)
HemosIL D-dimer HS 230 ng/mLa 99 (32.6) 13 (13.1) 12 (5.9) 2.24 (1.06-4.73)
(n=304) 300 ng/mLb 75 (24.7) 12 (16.0) 13 (5.7) 3.10 (1.41-6.80)
STA Liatest D-dimer 500 ng/mLa 102 (32.0) 12 (11.8) 13 (6.0) 1.96 (0.93-4.15)
(n=319) 700 ng/mLb 71 (22.2) 12 (16.9) 13 (5.2) 3.58 (1.63-7.85)
aResults calculated using the cut-off level  indicated by the manufacturers for VTE exclusion; bresults calculated using the cut-off level giving the results most comparable to
those obtained with the qualitative Clearview Simplify D-dimer assay. VTE: venous thromboembolism; HR: hazard ratio; CI: confidence interval. 
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test is to be used in clinical practice to stratify the risk
of VTE recurrence, assays other than that used in the
PROLONG study need to be independently assessed
with a similar management study. Some indications
can, however, be drawn from the present study, which
evaluated different quantitative D-dimer tests using
frozen plasma from patients enrolled in the PROLONG
study. 
The present analysis shows that quantitative D-
dimer assays may be useful in evaluating a patient’s
individual risk of VTE recurrence following a first
unprovoked event. These assays seem particularly
advantageous since they allow the selection of different
cut-off levels according to a patient’s characteristics.
We found that when the cut-off levels validated for use
in diagnostic strategies for exclusion of VTE in sympto-
matic patients were used, even when assessing VTE
recurrence risk, the percentage of subjects with abnor-
mal D-dimer results was higher than that recorded in
the qualitative assay; as a consequence, the rate of VTE
recurrence in subjects with abnormal D-dimer levels
was lower than that recorded in the PROLONG study.
These data suggest that slightly higher cut-off levels
than those used in diagnostic strategies used to rule out
Table 4. Results obtained with the different D-dimer assays in patients aged ≤70 or >70 years. For each assay the results obtained using
the lowest cut-off level giving a statistically significant hazard ratio are reported. 
D-dimer assay Cut-off N. (%) of patients (%) of VTE N. (%) of VTE HR
with abnormal recurrences in patients recurrences  in patients (95%CI) 
D-dimer with abnormal with normal 
D-dimer D-dimer
Patients aged ≤ 70 (n=196)
Clearview Simplify D-dimer − 33 (16.8) 5 (15.1) 6 (3.7) 4.52 (1.38-14.8)
VIDAS D-dimer Exclusion 600 ng/mL 54 (28.1) 6 (11.1) 5 (3.6) 3.29 (1.00-10.8)
Innovance D-DIMER 500 ng/mL 34 (29.6) 4 (11.8) 1 (1.2) 9.79 (1.09-87.6)
HemosIL D-dimer HS 250 ng/mL 36 (19.4) 5 (13.9) 6 (4.0) 3.74 (1.14-12.3)
STA Liatest D-dimer 700 ng/mL 24 (12.4) 4 (16.7) 7 (4.1) 4.62 (1.35-15.8)
Patients aged > 70 (n=125)
Clearview Simplify D-dimer − 48 (38.4) 7 (14.6) 7 (9.1) 1.69 (0.59-4.81)
VIDAS D-dimer Exclusion 1200 ng/mL 39 (31.2) 8 (20.5) 6 (7.0) 3.23 (1.12-9.33)
Innovance D-DIMER 900 ng/mL 40 (29.2) 8 (20.0) 8 (8.2) 2.73 (1.02-7.27)
HemosIL D-dimer HS 450 ng/mL 29 (24.4) 7 (24.1) 7 (7.8) 3.45 (1.21-9.85)
STA Liatest D-dimer 1000 ng/mL 35 (28.0) 7 (20.0) 7 (7.8) 2.84 (1.00-8.11)
VTE: venous thromboembolism; HR: hazard ratio; CI: confidence interval. 
Table 3. Results obtained with the different D-dimer assays according to the patients’ age. Data were calculated for each assay using the
cut-off levels shown in Table 2.
N. (%) of patients N. (%) of VTE N. (%) of VTE HR
with abnormal recurrences in patients recurrences in  patients (95%CI) 
D-dimer with abnormal D-dimer with normal D-dimer 
Clearview Simplify D-dimer
Patients ≤70 years (n=196) 33 (16.8) 5 (15.1) 6 (3.7) 4.52 (1.38-14.8)
Patients >70 years (n=125) 48 (38.4) 7 (14.6) 7 (9.1) 1.69 (0.59-4.81)
VIDAS D-dimer Exclusion Cut-off = 800 ng/mL
Patients  ≤70 years (n=192) 30 (15.0) 4 (13.3) 7 (4.3) 3.50 (1.02-12.0)
Patients > 70 years (n=125) 56 (44.8) 9 (16.1) 5 (7.2) 2.35 (0.79-7.00)
Innovance D-DIMER Cut-off = 800 ng/mL
Patients ≤70 years (n=115) 15 (13.0) 2 (13.3) 3 (3.0) 4.77 (0.80-28.6)
Patients > 70 years (n=137) 42 (30.7) 8 (19.0) 8 (8.4) 2.49 (0.94-6.65)
HemosIL D-dimer HS Cut-off = 300 ng/mL
Patients ≤70 years (n=185) 24 (13.0) 4 (16.7) 7 (4.3) 4.35 (1.27-14.9)
Patients > 70 years (n=119) 51 (42.8) 8 (15.7) 6 (8.8) 1.90 (0.66-5.47)
STA Liatest D-dimer  Cut-off = 700 ng/mL
Patients  ≤70 years (n=194) 24 (12.4) 4 (16.7) 7 (4.1) 4.62 (1.35-15.8)
Patients > 70 years (n=125) 47 (37.6) 8 (17.0) 6 (7.7) 2.39 (0.83-6.89)
VTE: venous thromboembolism; HR: hazard ratio; CI: confidence interval.
VTE (usually around 500 ng/mL for D-dimer assays
whose results are expressed in fibrinogen equivalent
units and around 250 ng/mL for those whose results are
expressed in D-dimer units)24 may be better suited for
predicting the risk of recurrence. 
As shown in Figures 1 and 2, when cut-off levels
were increased, the percentage of subjects with altered
results decreased and the rate of recurrence increased;
in contrast, the rate of recurrence in subjects with nor-
mal D-dimer levels remained substantially unchanged.
It seems, therefore, that selection of a progressively
higher D-dimer cut-off does not translate into a lower
negative predictive value. Our interpretation of these
data is that an abnormal D-dimer level is a stronger
positive predictor for the risk of VTE recurrence than a
normal D-dimer level is a negative predictor.
It is well known that D-dimer levels increase with
age, particularly in the presence of co-existing function-
al impairment, because of a combination of factors,
including reduced renal clearance, increased fibrinogen
levels and the presence of occult disease.25,26 It has been
shown that in healthy subjects D-dimer levels are
approximately four times higher in the highest age
quartile.25 As a result, it has been reported that the
specificity and hence diagnostic utility of D-dimer
measurements for excluding VTE is lower in older
patients.27-29 In one study, it was shown that the speci-
ficity of the VIDAS D-dimer assay improved when a
higher cut-off level was used in elderly patients with-
out any decrease in sensitivity.30 The PROLONG study
showed that abnormal Clearview Simplify D-dimer
results were significantly associated with an increased
risk of VTE recurrence; however, analyzing the results
according to the age of the patients, it was found that
the association did not reach statistical significance in
patients aged >70 years. Similar results have been
obtained for quantitative assays when a single cut-off
level is used for all patients. A theoretical advantage of
using quantitative D-dimer tests is that different
thresholds discriminating between abnormal and nor-
mal can be used according to the patients’ characteris-
tics. The present results support the use of different
cut-off levels depending on a patient’s age. Indeed,
using a higher cut-off value, abnormal D-dimer results
in the study were associated with a significant increase
in the risk of VTE recurrence even in elderly patients.
Some important limitations of the present study need
to be pointed out. First and foremost, this was a post-
hoc analysis of a prospective study. It is likely that the
hazard ratios calculated for the quantitative assays
were exaggerated since cut-off levels were determined
knowing which subjects had or had not had recurrent
VTE. Second, not all the patients enrolled in the PRO-
LONG study could be evaluated in the present analysis
because of the unavailability of frozen plasma aliquots
and the exclusion of those patients who had been ran-
domized to resume treatment with a vitamin K antag-
onist. The number of patients examined was, therefore,
lower than that in the PROLONG study; in particular
the number of recurrent VTE events was low, thus
affecting the accuracy of the findings and widening the
confidence intervals of estimates. This limitation is
even greater when different subgroups of patients were
analyzed according to age. Finally, each D-dimer assay
should be evaluated in specifically designed manage-
ment studies to prospectively validate their use in
assessing the risk of VTE recurrence.31 We do, however,
believe that the present results can be of some use for
further prospective studies.
Appendix
All the centers that participated in this study are affiliated
to the Italian Federation of Thrombosis Centers – FCSA. The
following is a list of study sites involved and the principal
investigators. The number of patients enrolled is given in
parentheses:
U.O. Angiologia e Malattie della Coagulazione “Marino
Golinelli”, Policlinico S.Orsola-Malpighi, Bologna – G. Pa-
lareti (n=112, Coordinating Center); I° Div. di Medicina
Interna - Centro Emostasi e Trombosi, Arcispedale Santa
Maria Nuova, Reggio-Emilia – A. Ghirarduzzi (n=51); A.O.
Istituti Ospitalieri, Cremona – S. Testa (n=48); Centro Re-
gionale Malattie Emorragiche e Trombotiche - Div. Emato-
logia, Ospedale S. Bortolo, Vicenza – A. Tosetto (n=21); Se-
zione Trasfusionale, Ospedale San Leopoldo Mandic,
Merate – N. Erba (n=15); Servizio di Prevenzione e Terapia
della Trombosi, Ospedale "Ex Busonera", Padova – V. Pengo
(n=15); Centro Sorveglianza Anticoagulati - Malattie della
Coagulazione e Angiologia Medica - Div. di Med. Interna,
Ospedale "S. Cuore di Gesu'", Gallipoli – L. Ria (n=13);
Centro Emostasi, Ospedale Regionale, Parma – C. Pattacini
(n=10); Laboratorio Analisi - Ambulatorio per il Controllo
della Terapia Anticoagulante Orale, Presidio Ospedaliero di
Faenza – E. Bucherini (n=9); Laboratorio Analisi - Divisione
di Cardiologia, Ospedale di Bentivoglio – E. Cerè (n=9);
Laboratorio di Patologia Clinica, Presidio Ospedaliero
S.Maria Incoronata dell'Olmo, Cava dei Tirreni – C. Villani
(n=8); Centro Trombosi, A.O. di Careggi Universita' di
Firenze – D. Prisco (n=4); U.O. Medicina Interna, Policlinico
Universitario Messina – A. Trifiletti (n=4); Centro per lo
Studio delle Coagulopatie a Rischio Trombotico, Osp.
Galliera, Genova – A. Schenone (n=2).
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